Prostatype Genomics AB (OSTO:PROGEN) Tariff Resilience Score: 0/10 (As of Jul. 05, 2026)


OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
25 GF Score
Price kr0.33
GF Value kr0.11
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Tariff Resilience Score?

Prostatype Genomics AB has the Tariff Resilience Score of 0, which implies that the company might have .

Prostatype Genomics AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Prostatype Genomics AB might have .

Prostatype Genomics AB  (OSTO:PROGEN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Prostatype Genomics AB Tariff Resilience Score Related Terms

OSTO:PROGEN
25GF Score
Prostatype Genomics AB OSTO:PROGEN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.33 is trading 200% above its estimated GF Value™ of kr0.11. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • Tariff Resilience Score: 0
  • GF Value™: kr0.11 vs. price of kr0.33 (200% above fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score

Get the complete analysis for OSTO:PROGEN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.33
Price
kr0.11
GF Value